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Abstract
Electrolyte and mineral disturbances remain a major concern in patients undergoing continuous renal replacement therapy (CRRT);
however, it is not clear whether those imbalances are associated with adverse outcomes in patients with septic acute kidney injury
(AKI) undergoing CRRT. We conducted a post-hoc analysis of data from a prospective randomized controlled trial. A total of 210
patients with a mean age of 62.2 years (136 [64.8%] males) in 2 hospitals were enrolled. Levels of sodium, potassium, calcium, and
phosphate measured before (0hour) and 24 hours after CRRT initiation. Before starting CRRT, at least 1 deﬁciency and excess in
electrolytes or minerals were observed in 126 (60.0%) and 188 (67.6%) patients, respectively. The excess in these parameters was
greatly improved, whereas hypokalemia and hypophosphatemia became more prevalent at 24 hours after CRRT. However, 1 and 2
or more deﬁciencies in those parameters at the 2 time points were not associated with mortality. However, during 28 days, 89
(71.2%) deaths occurred in patients with phosphate levels at 0hour of ≥4.5mg/dL as compared with 49 (57.6%) in patients with
phosphate levels<4.5mg/dL. The 90-daymortality was also signiﬁcantly higher in patients with hyperphosphatemia. Similarly, in 184
patients who survived at 24 hours after CRRT, hyperphosphatemia conferred a 2.2-fold and 2.6-fold increased risk of 28- and 90-day
mortality, respectively. The results remained unaltered when the serum phosphate level was analyzed as a continuous variable.
Electrolyte and mineral disturbances are common, and hyperphosphatemia may predict poor prognosis in septic AKI patients
undergoing CRRT.
Abbreviations: AKI = acute kidney injury, APACHE II = acute physiology and chronic health evaluation II, CCI = Charlson
comorbidity index, CI = conﬁdence interval, CRP = C-reactive protein, CRRT = continuous renal replacement therapy, eGFR =
estimated glomerular ﬁltration rate, FiO2 = fraction of inspired oxygen, HR = hazard ratio, ICU = intensive care unit, MAP = mean
arterial pressure, SOFA = sequential organ failure assessment.
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Acute kidney injury (AKI) commonly occurs in critically ill
patients in the intensive care unit (ICU).[1] The incidence rate ofEditor: Muhammed Mubarak.
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1AKI varies depending on the deﬁnition used and is reported to be
7% in all hospitalized patients[2] and up to 60% in ICU
patients.[3] The importance of AKI has been highlighted because
it is associated with high morbidity and mortality rates.[4] It is
also associated with increased costs[5] and length of hospital
stay.[6] Moreover, patients with AKI are more likely to develop
chronic kidney disease, including end-stage renal disease than
those without AKI.[7] Sepsis is a devastating medical condition
triggered by an immune response to infection, leading to multiple
complications. AKI frequently develops as a consequence of
sepsis, and its incidence has been reported to be 19% in patients
with sepsis, 23% in those with severe sepsis, and 51% in those
with septic shock, when blood cultures are positive.[8] Notably,
septic AKI is one of the life-threatening manifestations of multiple
organ dysfunction syndrome and has been shown to be
independently associated with adverse clinical outcomes.[9]
Electrolyte or mineral imbalances are common ﬁndings inmany
serious conditions, including septicAKI.However, the incidenceof
these alterations in critically ill patients is unclear. Adekola et al[10]
reported that >66.78% of patients in the ICU had multiple
electrolyte and acid-base abnormalities. It is important tomaintain
these parameters within the physiologic levels to prevent
complications and adverse outcomes because electrolytes and
minerals play important roles in protecting cellular function, tissue
perfusion, and acid–base homeostasis.[11,12] Not surprisingly,
Jung et al. Medicine (2016) 95:36 Medicinecontinuous renal replacement therapy (CRRT) has become the
modality of choice in critically ill patients with AKI as it is more
effective in correctinguremia, electrolyte andmineral disturbances,
acid-base disorder, and volume overload. In addition, CRRT can
provide immune modulation through the convective and adsorp-
tive removal of various immune mediators.[13]
Although electrolyte and mineral disturbances are largely
improved with dialysis treatment, this issue has not yet been
completely resolved even in patients undergoing CRRT. In fact,
overcorrection often causes serious problems such as neurologic
dysfunction, conductance abnormalities, arrhythmia, and gastro-
intestinal hypomotility.[14–16] On the other hand, insufﬁcient
correction remains despite CRRT and is sometimes ignored in
clinical practice.When septic AKI occurs, the clinical outcomes are
primarily determined by the propermanagement of primary illness
and the presence or absence of multiorgan involvement. However,
it is not clear whether electrolyte and mineral disturbances are
associated with adverse outcomes in patients with septic AKI
undergoing CRRT. Therefore, we aimed to investigate the
incidence, clinical course, and clinical utility as prognosticmarkers
of the altered levels of electrolytes and minerals in these patients.2. Materials and methods
2.1. Patient selection
We performed a post-hoc analysis of data from our recent study,
“Effects of High-volume Continuous Renal Replacement
Therapy on Inﬂammatory Mediators and Outcomes in Patients
with Septic Acute Kidney Injury” (NCT01191905). Brieﬂy, this
prospective randomized controlled open-label trial was con-
ducted at Yonsei University Health System Severance Hospital
and Seoul National University Hospital between January 2011
and August 2014. The aim of the study was to compare high and
conventional doses of CRRT in patients with septic AKI who
underwent CRRT. The detailed treatment was described
elsewhere.[17] Patients were included if they met the following
criteria: consensus criteria for sepsis,[18] injury stage of the RIFLE
(risk, injury, failure, loss, end stage) criteria[19] or more (>2-fold
increase in serum creatinine or urine output of <0.5mL/kg/h for
12hours), and absence of other established nonsepsis-related
cause of AKI. Patients were excluded if they met the following
criteria: age<20 years or>80 years, with a life expectancy of<3
months, with Child-Pugh class C liver cirrhosis, pregnant or
lactating, andwith a history of dialysis before the study. Finally, a
total of 210 patients were enrolled excluding 2 patients with
missing data. The study was approved by the institutional review
board of the 2 participating hospitals and followed the provisions
of the Declaration of Helsinki. We obtained informed written
consent from all the enrolled participants.
2.2. Clinical and biochemical data collection
Demographic and clinical data such as age, sex, body mass index,
and comorbidities were recorded at the time of CRRT initiation.
Biochemical data for electrolyte andmineral levels, suchas sodium,
potassium, calcium, andphosphate,weremeasured before starting
CRRT (0hour) and at 24hours after CRRT initiation. Calcium
levels were corrected by using serum albumin levels (corrected
calcium = calcium [mg/dL] + 0.8  [4 – serum albumin {g/dL}]).
The reference ranges of each electrolyte andmineral are as follows:
sodium, 135–145mEq/L; potassium, 3.5–5.5mEq/L; calcium and
corrected calcium,8.5–10.5mg/dL; andphosphate, 2.5–4.5mg/dL.
In addition, the following biochemical laboratory data were2collected at both time points: hemoglobin, white blood cell, serum
creatinine, albumin, lactate, aspartate aminotransferase, alanine
aminotransferase, and total bilirubin levels. The estimated
glomerular ﬁltration rate (eGFR) was calculated by using the
chronic kidney disease epidemiology collaboration equation.[20]
The data also included the age-adjusted Charlson comorbidity
index (CCI), Sequential Organ Failure Assessment (SOFA)
score, and Acute Physiology and Chronic Health Evaluation II
(APACHE II) score. Although the APACHE II is the most well-
known system that provides prognostic information for ICU
patients, the score does not include speciﬁc criteria for kidney
function.[21] Thus, we used the SOFA score for this study analysis.2.3. Study end points
The study endpointwasdeath that occurredwithin 28and90days
after CRRT initiation. In addition, the duration of CRRT and
length of hospital stay after CRRT initiation were also analyzed.2.4. Statistical analysis
All statistical analyses were performed by using SPSS forWindows
version 23.0 (IBMCorp., Armonk,NY). Continuous variables are
expressed as the mean ± standard deviation or median
(interquartile range), whereas categorical variables are expressed
as a number (percentage). Comparisons between 2 groups or
among 3 groups were done through an analysis of variance or
Student’s t test for continuous variables, and with the chi-squared
test or Fisher’s exact test for categorical variables. The normality of
distribution was conﬁrmed by using the Kolmogorov–Smirnov
test. Cumulative survival curves were derived by using the
Kaplan–Meier method, and differences between curves were
compared through the log-rank test. Cox proportional hazards
analysis was performed to determine the relationship between
the abnormality in each electrolyte and mineral, and mortality.
P-values <0.05 were considered statistically signiﬁcant.
3. Results
3.1. Patient characteristics
The baseline clinical characteristics and laboratory ﬁndings of the
study subjects are shown in Table 1. The mean age of the
participants was 62.2 ± 12.9 years, and 136 (64.8%) of them
were men. Among the 210 patients, 57 (27.3%) had diabetes and
17 (8.0%) had cardiovascular diseases. The mean baseline eGFR
at the time of CRRT initiation was 26.30±22.39mL/min 1.73
m2. The mean age-adjusted CCI was 4.64±2.62. The SOFA
score was 14.18±3.10, and the APACHE II score was 28.72±
7.30. The mean arterial pressure (MAP) at 0hour was 78.81±
14.49mm Hg. A total of 175 (83.3%) patients received
mechanical ventilation, and the mean fraction of inspired oxygen
(FiO2) was 0.58±0.24. The mean white blood cell count and
C-reactive protein levels were 11,350mL (5,037–18,815mL) and
18.43mg/L (9.35–39.80mg/L), respectively.3.2. Electrolyte or mineral deﬁciencies and excess before
and 24hour after CRRT initiation
Table 2 shows the deﬁciencies and excess of each electrolyte and
mineral at 0 and 24hours after CRRT application. Overall
deﬁciencies or excesses in a single electrolyte or mineral were
observed in 126 (60.0%) and 188 (67.6%) patients, respectively,
before starting CRRT (0hour). The most frequent disturbances
Table 1
Baseline characteristics of subjects.
Total (n=210)
Age, y 62.2±12.9
Male, % 136 (64.8)
Hypertension, % 100 (47.6)
Diabetes mellitus, % 57 (27.3)
Heart failure, % 18 (8.6)
Ischemic heart disease, % 13 (6.2)
Myocardial infarction, % 4 (1.9)
Cerebrovascular disease, % 11 (5.3)
COPD, % 12 (5.7)
Mechanical ventilation, % 175 (83.3)
CCI 2.94±2.15
Age-adjusted CCI 4.64±2.62
BMI (kg/m2) at ICU admission 23.26±4.22
eGFR (mL/min/1.73 m2) at admission 72.58±45.10
eGFR at CRRT initiation (mL/min/1.73 m2) 26.30±22.39
SOFA score 14.18±3.10
APACHE II score 28.72±7.30
Systolic blood pressure, mm Hg 111.72±20.52
Diastolic blood pressure, mm Hg 62.30±13.90
Mean arterial pressure, mm Hg 78.81±14.49
Hemoglobin, g/dL 9.42±1.93
White blood cell, mL 11350 [5037 – 18815]
Albumin, g/dL 2.47±0.53
Blood urea nitrogen, mg/dL 62.48±32.60
Creatinine, mg/dL 3.09±1.77
Aspartate aminotransferase, IU/L 89.50 [38.00–356.00]
Alanine transaminase, IU/L 39.50 [16.00–185.00]
Bilirubin, mg/dL 1.90 [0.90–5.65]
CRP, mg/L 18.43 [9.35–39.80]
Lactate, mmol/L 6.60±5.11
FiO2 0.58±0.24
pH 7.30±0.11
PaO2, mm Hg 103.97±81.88
PaCO2, mm Hg 38.71±16.27
Base excess, mmol/L –6.90 [–11.13 to –3.80]
Data are expressed as mean ± standard deviations, median (interquartile range), or numbers (%).
APACHE II= acute physiology and chronic health evaluation II, BMI=body mass index, CCI=Charlson
comorbidity index, COPD= chronic obstructive pulmonary disease, CRP=C-reactive protein, CRRT=
continuous renal replacement therapy, eGFR= estimated glomerular ﬁltration rate, FiO2= fraction of
inspired oxygen, ICU= intensive care unit, SOFA= sequential organ failure assessment score.
Jung et al. Medicine (2016) 95:36 www.md-journal.com(deﬁciency or excess) were hypocalcemia (37%) and hyper-
phosphatemia (59.5%) (Table 2).
CRRT during the ﬁrst 24 hours greatly improved the excess in
electrolytes and minerals. However, disturbances in these
parameters were still common at 24 hours (Fig. 1). ForTable 2
Electrolyte or mineral deﬁciencies and excess before starting conti
replacement therapy initiation.
0 h 24 h
Mean±SD Mean ± SD P
Sodium 138.24±8.25 137.54±4.34 0.22
Potassium 4.39±0.94 3.83±0.73 <0.001
Calcium, Ca 7.61±1.20 8.35±0.78 <0.001
Corrected Ca 8.82±1.16 9.46±0.74 <0.001
Phosphate 5.66±2.48 3.99±1.76 <0.001
Data are expressed mean ± standard deviations and numbers (%).
Calcium (mg/dL); corrected Ca (mg/dL); phosphate (mg/dL); potassium (mEq/L); sodium (mEq/L).
SD= standard deviation.
3deﬁciencies, hyponatremia, hypokalemia, hypocalcemia, and
hypophosphatemia were found in 35 (19.4%), 51 (28.3%), 15
(8.5%), and 36 (19.6%) patients, respectively. In contrast, for
excess, hypernatremia (n=8, 4.4%), hyperkalemia (n=2, 1.1%),
and hyperphosphatemia (n=57, 31.0%) occurred at lesser rates
than those at 0hour (Table 2).
3.3. CRRT duration, hospital stays, and mortality
Among the 210 patients, 138 (65.7%) and 162 (77.1%) deaths
occurred during 28 and 90 days. Twenty-two (10.5%) patients
died during 24hours after CRRT initiation. Overall, the median
duration of CRRT and the median length of hospital stay after
CRRT initiation were 3.90 (2.20–7.24) and 10.45 (2.97–31.33)
days, respectively. The duration of CRRT (3.94 [3.21–5.18] vs
3.91 [1.81–8.99], P=0.003) and hospital stay (34.53
[19.40–70.16] vs 6.20 [2.33–19.74], P<0.001) were signiﬁcant-
ly longer in survivors than in nonsurvivors (Supplementary
Table 1, http://links.lww.com/MD/B261).3.4. Clinical outcomes according to electrolyte or mineral
disturbances before and at 24hours after CRRT initiation
We compared the mortality rates according to the deﬁciencies and
excesses of electrolytes andminerals (Supplementary Table 2, http://
links.lww.com/MD/B261). Any alterations in sodium, calcium, and
potassium levels at 0 and 24hours were not associated with
mortality (data not shown). In addition, the serum levels of these
parameters at 0hour did not differ between survivors and
nonsurvivors (Supplementary Table 3, http://links.lww.com/MD/
B261). However, 89 (71.2%) deaths occurred in hyperphosphate-
mic patients as compared with 2 (33.3%, P=0.08) in hypophos-
phatemic patients and 47 (59.5%, P=0.02) in normophosphatemic
patients during 28 days. During 90 days, 105 (84.0%) patients with
hyperphosphatemia died as compared with 57 (67.1%) patients
with phosphate levels<4.5mEq/L (P=0.03). The serum phosphate
levels were also higher in nonsurvivors than in survivors (4.97±
2.78mg/dL vs 5.79±2.53mg/dL, P=0.04). This pattern was
consistent when analyzed by using phosphate levels at 24hours
(3.42±1.37mg/dL vs 4.21±1.84mg/dL, P=0.01) (Supplementary
Table 3, http://links.lww.com/MD/B261). The length of hospital
stay after CRRT initiation was shorter in patients with hyper-
phosphatemia at 24hours than those for the normal or low-level
group (19.63 [6.28–35.53] days vs 15.81 [6.39–33.58] days vs 3.94
[1.91–22.70] days, P=0.02) (Supplementary Table 4, http://links.
lww.com/MD/B261). This ﬁnding was not observed for sodium,
potassium, and calcium. We further analyzed whether 2 or more
deﬁciencies in electrolytes and minerals could predict adversenuous renal replacement therapy and 24h after continuous renal
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Figure 1. Electrolyte or mineral deﬁciencies and excess before starting CRRT and 24hours after CRRT initiation: 1, deﬁciency; 2, normal; 3, excess. CRRT=
continuous renal replacement therapy.
Jung et al. Medicine (2016) 95:36 Medicineoutcomes. Compared with a single-deﬁciency group, groups with 2
ormoredeﬁcienciesdidnot showan increasedmortality rate (Fig. 2).
3.5. Hyperphosphatemia predicts adverse outcomes
Because more deaths occurred in the hyperphosphatemic group
than in the other 2 groups, we further investigated whether
phosphate levels could predict clinical adverse outcomes. First,4there were only 6 patients with phosphate levels <2.5mg/dL at 0
hour; thus, thepatientsweredivided into2groups:<4.5mg/dLand
≥4.5mg/dL. Most baseline characteristics were comparable
between groups before CRRT initiation (Supplementary Table 5,
http://links.lww.com/MD/B261). However, eGFR was signiﬁcant-
ly lower inpatientswith hyperphosphatemia (31.5±30.7 vs 22.7±
13.2mL/min 1.73m2, P=0.01). We constructed 3 different Cox
models, as presented in Table 3. The crude hazard ratios (HRs) for
Figure 2. Kaplan–Meier plots for 28- and 90-day mortality according to single and 2 or more deﬁciencies in electrolytes or minerals before starting CRRT (A and B)
and 24hours after CRRT initiation (C and D), Group 1 (single deﬁciency); Group 2 (2 or more deﬁciencies), CRRT=continuous renal replacement therapy.
Jung et al. Medicine (2016) 95:36 www.md-journal.comthe 28- and 90-day mortality rates compared with normophos-
phatemia or hypophosphatemia were 1.44 and 1.47 (95%
conﬁdence interval [CI], 1.01–2.03, P=0.04; 95% CI,
1.07–2.02, P=0.02), respectively. In a model 2 adjusted for age,
sex, and body mass index (BMI), hyperphosphatemia was also
associated with an increased risk of death. Finally, in a fully
adjusted model after additional adjustment for CCI, SOFA score,
and residual kidney function, this association becamemore evident
(Table 3). Next, patients were classiﬁed into 3 groups according to
deﬁcient, normal, and excess phosphate levels at 24hours after
CRRT (Supplementary Table 6, http://links.lww.com/MD/B261).
The hyperphosphatemic group was younger (P=0.18), had higher
BMI (P=0.01) and SOFA score (P<0.001), and had lower MAP
(P=0.002). After full adjustment of these factors, hyperphospha-
temia conferred a 2.2-fold and 2.6-fold increased risk of 28-day
(HR, 2.25; 95% CI, 1.40–3.61; P<0.001) and 90-day mortality
(HR, 2.65; 95% CI, 1.71–4.12; P<0.001) compared with5normophosphatemia. When the phosphate level was treated as a
continuous variable, hyperphosphatemia was a signiﬁcant predic-
tor of 28-day mortality (HR, 1.36 per 1mg/dL increase; 95% CI,
1.20–1.54;P<0.001) and90-daymortality (HR, 1.32per 1mg/dL
increase; 95% CI, 1.17–1.48; P<0.001) (Table 4 and Fig. 3).
4. Discussion
Electrolyte, mineral, and acid–base disturbances commonly
occur in AKI patients.[22] Much effort has been made to maintain
homeostasis in clinical practice. In particular, CRRT greatly
improves the abnormalities of these parameters; however, it can
often cause overcorrection, and suboptimal correction remains a
concern. This study evaluated the incidence, clinical course, and
prognostic implication of electrolyte and mineral disturbances in
septic AKI patients undergoing CRRT. We found that, as
expected, electrolyte andmineral disturbances were common and
Table 3
Cox proportional hazard regression analysis for 28- and 90-day mortality before starting continuous renal replacement therapy with all-
cause mortality.
Phosphate as a categorical variable (≥ 4.5 vs <4.5 mg/dL)
∗
Phosphate as a continuous variable (per 1 mg/dL increase)
HR (95% CI) P HR (95% CI) P
28-day
Model 1 1.44 (1.01–2.03) 0.04 1.04 (0.98–1.10) 0.24
Model 2 1.46 (1.03–2.07) 0.04 1.05 (0.99–1.11) 0.14
Model 3 1.59 (1.10–2.29) 0.01 1.08 (1.00–1.15) 0.04
90-day
Model 1 1.47 (1.07–2.02) 0.02 1.05 (1.00–1.10) 0.07
Model 2 1.49 (1.08–2.06) 0.02 1.06 (1.00–1.11) 0.05
Model 3 1.64 (1.18–2.29) 0.003 1.09 (1.02–1.16) 0.01
∗
Phosphate level <4.5 mg/dL is a referent.
Model 1: unadjusted.
Model 2: Age, gender, BMI at ICU admission.
Model 3: Model 2 + CCI, SOFA score, eGFR (0 h).
BMI=bodymass index, CCI=Charlson comorbidity index, CI=conﬁdence interval, eGFR= estimated glomerular ﬁltration rate, HR=hazard ratio, ICU= intensive care unit, SOFA= sequential organ failure assessment.
Jung et al. Medicine (2016) 95:36 MedicineCRRT largely corrected these abnormalities in the analyzed
patients. Notably, a single deﬁciency and 2 or more deﬁciencies of
electrolytes or minerals were not associated with adverse
outcomes. However, hyperphosphatemia was signiﬁcantly
associated with an increased risk of 28- and 90-day mortality
rates in septic AKI patients undergoing CRRT.
It is well known that deﬁciencies in electrolytes and minerals
can increase morbidity, if not properly treated.[23] In addition,
many studies have shown that critically ill patients with
hypokalemia[24] or hypophosphatemia[25,26] are more likely to
die than patients without these abnormalities. In contrast to these
previous studies, in this study, any deﬁciencies in sodium,
potassium, calcium, and phosphate were found not to be related
to increased mortality rates in septic AKI patients undergoing
CRRT. Before initiating CRRT, deﬁciencies in sodium and
calcium were more common than deﬁciencies in potassium and
phosphate. However, hyponatremia and hypocalcemia were
much improved after CRRT. In general, a CRRT solution
contains 140mEq/L sodium and 2.5–3.5mEq/L calcium; thus,
sodium and calcium deﬁciencies can be corrected by diffusion. In
contrast, hypokalemia and hypophosphatemia became more
prevalent 24hours after CRRT. This overcorrection can
commonly occur during CRRT. To prevent this, CRRT solutionsTable 4
Cox proportional hazard regression analysis for 28- and 90-day m
replacement therapy initiation.
Phosphate as a categorical variable (≥4.5 vs 2.5 to 4.5 vs <2.5
HR (95% CI) P
28-day
Model 1 2.11 (1.41–3.16) <0.001
Model 2 3.12 (2.01–4.86) <0.001
Model 3 2.25 (1.40–3.61) <0.001
90-day
Model 1 2.54 (1.76–3.67) <0.001
Model 2 3.52 (2.24–5.30) <0.001
Model 3 2.65 (1.71–4.12) <0.001
∗
Phosphate level of 2.5–4.5 mg/dL is a referent.
Model 1: unadjusted.
Model 2: Age, gender, BMI at ICU admission.
Model 3: Model 2 + CCI, SOFA score, urine output (24 h).
BMI=body mass index, CCI=Charlson comorbidity index, CI= conﬁdence interval, HR=hazard ratio, I
6containing potassium and phosphate have been commercially
available. Unfortunately, our centers do not have these solutions
and thus cannot use them in the ICU. Even though the samples
were collected and stored at 0 and 24hours according to the
original study protocol, we additionally measured serum levels of
electrolytes and minerals at 10–12hours after CRRT initiation
for early detection of disturbances in these parameters in AKI
patients, particularly those on CRRT. Presumably, prompt
correction of potassium and phosphate deﬁciencies might be
helpful to avoid serious complications. Another possible
explanation is the unique patient inclusion of this study; we
only included patients with septic AKI requiring CRRT. In fact,
septic AKI is apparently distinct from nonseptic AKI in
pathophysiology and severity.[27] In sepsis, the systemic inﬂam-
matory response triggered by infectious insult deteriorates failure
in multiple organs and systems, subsequently resulting in
catastrophic physiological derangements. Therefore, it can be
presumed that the hemodynamic alteration and deterioration due
to sepsis-induced systemic inﬂammatory response syndrome
might overwhelm the impact of electrolyte and mineral
disturbances in terms of affecting mortality.
In this study, we showed that hyperphosphatemia was
signiﬁcantly associated with an increased risk of death. Inortality in 184 patients who survived 24h after continuous renal
mg/dL)
∗
Phosphate as a continuous variable (per 1 mg/dL increase)
HR (95% CI) P
1.33 (1.20–1.47) <0.001
1.46 (1.31–1.62) <0.001
1.36 (1.20–1.54) <0.001
1.36 (1.21–1.47) <0.001
1.43 (1.29–1.59) <0.001
1.32 (1.17–1.48) <0.001
CU= intensive care unit, SOFA= sequential organ failure assessment.
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Figure 3. Kaplan–Meierplots for28- and90-daymortality according tophosphate levelsbefore startingCRRT (AandB) and24hoursafterCRRT initiation (CandD),Group
1 (below normal levels) <2.5mg/dL; Group 2 (normal levels) 2.5–4.5mg/dL; Group 3 (elevated levels) >4.5mg/dL. CRRT=continuous renal replacement therapy.
Jung et al. Medicine (2016) 95:36 www.md-journal.comcontrast to our ﬁndings, several previous studies have shown that
hypophosphatemia was a signiﬁcant predictor of adverse
outcomes in critically ill patients. In fact, phosphate is a key
component of bone and cell membranes, is essential in all body
functions requiring energy (as adenosine triphosphate), and is
especially important in nerve and muscle function.[28] Hypo-
phosphatemia is caused by various conditions in ICU patients,
such as sepsis, diuretic use, total parenteral nutrition, and
gastrointestinal wasting.[29–32] Its harmful effects can be
exempliﬁed by decreased myocardial contraction, increased
development of arrhythmia, impaired response to vasopressors,
and decreased granulocyte phagocytic activity.[33–37] The reason
for the discrepancy in ﬁndings concerning phosphate levels and
mortality among studies is unclear. Interestingly, most of the
adverse effects caused by hypophosphatemia result from very
severe phosphate deﬁciency. In many previous studies, severe
hypophosphatemia was deﬁned as a serum phosphate level of
<1.0mg/dL.[38–40] By using this deﬁnition in our study, severe
hypophosphatemia was not observed in our subjects at 24hours
after CRRT. In addition, most patients with phosphate levels
<2.5mg/dL at 0hour had phosphate levels of 2.0–2.5mg/dL and
only 10 patients had phosphate levels <2.0mg/dL at 24hours.
We strictly followed a protocol concerning the supplementation
for deﬁciencies in electrolytes and minerals, and this can explain
the rare incidence of severe hypophosphatemia in our study.
An acute decrease in phosphate levels during dialysis treatment
is also important in determining adverse outcomes. Demirjian
et al[41] showed that patients with a decline in phosphate to <2
mg/dL during CRRT had prolonged respiratory failure requiring
tracheostomy. In our study, there were only 10 patients whose
phosphate levels declined to <2mg/dL at 24hours after CRRT.
These patients were not signiﬁcantly associated with an increased
mortality as compared with patients with phosphate levels >2
mg/dL (HR, 1.12; 95%CI, 0.80–1.57; P=0.50, data not shown).
The underlying mechanism responsible for the high mortality in
hyperphosphatemic patients is largely presumptive. It is possible
that phosphate simply reﬂects disease severity because it is released7from damaged cells. Various types of cell death have been
suggested in sepsis.[42] Besides phosphate, other danger signals and
inﬂammatory cytokines are also released upon cell death and may
play more important roles in the development of life-threatening
conditions.[43–45] Direct phosphate toxicity is also plausible.
Increased phosphate from dead cells subsequently promotes
vascular inﬂammation[46,47] and triggers phosphate inﬂux into
cells, resulting in increasedmitochondrialmembrane potential and
reactive oxygen species production.[48] This can produce a vicious
cycle and further aggravate cell death. In fact, a number of studies
have shown that patients with increased phosphate levels are more
likely to develop cardiovascular diseases[47,49,50] and chronic
kidney disease,[51] even end-stage renal disease.[51]
This study has some limitations. First, as this is a post-hoc
analysis of our prior randomized controlled trial, causality is
uncertain and the results should be interpreted with caution. In
addition, the small sample size is another limitation, as it may
result in a lack of statistical power. Second, magnesium is also an
important mineral and its deﬁciency is common in AKI patients;
however, we did not include magnesium imbalance in the
reported data because magnesium levels were not measured in
>50% of the patients. Nevertheless, we performed further
analysis in this limited number of patients and found that
magnesium disturbances did not affect mortality (data not
shown). Third, further analysis with extended follow-up data,
such as phosphate levels measured at 72hours, would be helpful
to conﬁrm our ﬁndings. However, septic AKI is a devastating
medical condition and many patients have died while receiving
CRRT. We analyzed 146 patients who survived at 72hours after
CRRT, by collecting additional blood samples, and found that
hyperphosphatemia still remained a signiﬁcant risk factor of
death (HR, 2.25; 95% CI, 0.13–4.89; P=0.04, data not shown).
Finally, the original study aimed to evaluate effects of high (80
mL/kg/h) versus conventional (40mL/kg/h) volume on clinical
outcomes; thus, the greater deﬁciencies in electrolytes and
minerals might be attributed to high-volume treatment. Howev-
er, there were no differences in the changes of these parameters
[24] Hessels L, Hoekstra M, Mijzen LJ, et al. The relationship between serum
Jung et al. Medicine (2016) 95:36 Medicineafter 24-h CRRT between the 2 groups. This ﬁnding suggests that
disturbances in electrolytes and minerals are not further
improved by high-volume treatment compared with treatment
with the conventional volume.
In conclusion, this study showed that electrolyte and mineral
disturbances are common and hyperphosphatemia may portend a
poorprognosis insepticAKIpatientsundergoingCRRT.Ifphosphate
is a biomarker that can reﬂect disease severity, then more careful
attention should be paid to patients with increased phosphate levels.References
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